Clinical Trial Search

Primary: Area Under the Plasma Concentration-time Curve (AUC) From Time Zero (Pre-dose) Extrapolated to Infinity (AUC[0-inf]) for Plasma Gepotidacin — 15894.7; 19505.7; 25415.5…

Primary: Change in the Liver Triglycerides (TG). — 13.2; 6.4; 12.3; 10.6 percentage of liver triglycerides

Primary: Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Time of the Last Quantifiable Concentration (AUC 0-t) of Preladenant After a Single Dose of…

Primary: Hepatic Fatty Acid Oxidation — 0.052; 0.045; 0.042 micromol/ml/min

Primary: Pharmacokinetic (PK) Parameter of Voxilaprevir: AUClast — 2058.5; 3872.5; 500.1; 601.2 h*ng/mL

Primary: Number of Events of ALT Elevation After Baseline, Controlling for APRI Score and Other Variables — 9; 4 events — p=0.02

Primary: Maximum Observed Plasma Concentration (Cmax) of Entrectinib — 296.140; 213.570; 183.680; 235.990 nmol/L

Primary: Pharmacokinetic (PK) Parameter: AUClast of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate) — 160.6…

Primary: Area Under the Plasma Concentration Versus Time Curve From 0 Hours to Infinity (AUC0-∞) of Doravirine — 53.9; 54.6 µM*hr

Primary: Part 1: Maximum Observed Plasma Concentration (Cmax) of NAL ER — 3.30; 7.67; 13.9; 18.7 nanogram per milliliter (ng/mL)

Primary: Detection Rate of Common Bile Duct Before and After Dissection Using Near Infra-red Light — 64; 157; 159; 243 Participants

Primary: Mean (SD) Pharmacokinetic (PK) Parameter Area Under Concentration Time Curve From Zero to Infinity (AUC0-oo) — 600; 731; 720 ng*hr/mL

Primary: Hepatic Insulin Sensitivity Index (HISI) — 0.8; 1.4 [10000/(μmol/min)x(mU/L)] — p=<0.019

Primary: Feasibility of Using Indwelling Tunneled Pleural Catheters for the Management of Hepatic Hydrothorax — 25 Participants

Primary: Percent Change From Baseline in Hepatic Fat — -35.73; -18.04; 8.63 Percent change — p=<0.001